# EDGAR Filing Document

**Accession Number:** 0001750149
**File Stem:** 0001193125-25-180889
**Filing Date:** 2025-8
**Character Count:** 43198
**Document Hash:** 6840ea316b9b3365306387e7f5d9e089
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-180889.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001193125-25-180889

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 39

**CONFORMED PERIOD OF REPORT**: 20250814

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inhibikase Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001750149
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 263407249
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39676
- **FILM NUMBER:** 251220563

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 N. WEST STREET, SUITE 1200
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** (302) 295-3800

**MAIL ADDRESS:**
- **STREET 1:** 1000 N. WEST STREET, SUITE 1200
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): August 14, 2025

## INHIBIKASE THERAPEUTICS, INC.

#### (Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39676** | **26-3407249** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |
| **1000 N. West Street, Suite 1200** | **1000 N. West Street, Suite 1200** |  |
| **Wilmington, DE** | **Wilmington, DE** | **19801** |
| **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (302) 295-3800

#### N/A

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.001 par value | IKT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02.** | **Results of Operations and Financial Condition.**  |

---

On August 14, 2025, Inhibikase Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure**  |

---

On August 14, 2025, Inhibikase Therapeutics, Inc. updated its corporate presentation for use in meetings with investors, analysts and others from time to time. A copy of the presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.2 attached hereto) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits.

99.1 [Press Release issued by Inhibikase Therapeutics, Inc., dated August 14, 2025, furnished herewith.](d946023dex991.htm)

99.2 [Corporate Presentation of Inhibikase Therapeutics, Inc., dated August 14, 2025, furnished herewith.](d946023dex992.htm)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: August 14, 2025 | INHIBIKASE THERAPEUTICS, INC. | INHIBIKASE THERAPEUTICS, INC. |
|  | By: | /s/ Mark Iwicki |
|  |  | Mark Iwicki |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g946023g58z24.jpg)

**Inhibikase Therapeutics Announces Second Quarter** 

**2025 Financial Results and Highlights Recent Activity** 

*August 14, 2025 —* Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments.

"During our second quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH," said Mark Iwicki, Chief Executive Officer of Inhibikase. "We have now finalized our study protocol, and we expect to initiate our Phase 2b clinical study of IKT-001, our re-engineered prodrug of imatinib mesylate, in PAH in the second half of 2025."

Multiple studies including both Phase 2 and the Phase 3 IMPRES study previously demonstrated that imatinib mesylate ("imatinib"), an anti-proliferative tyrosine kinase inhibitor, was highly efficacious in PAH. Notably in the IMPRES study, patients that maintained 400 mg of imatinib for greater than 50% of the treatment period showed a placebo adjusted 45-meter improvement in 6-minute walk distance ("6MWD") which represents best-in-class improvements for patients afflicted by PAH. More recently, a contemporary study in the *American Journal of Respiratory and Critical Care Medicine* demonstrated that higher exposures of imatinib were associated with a larger improvement in total pulmonary resistance ("TPR"). The 400 mg dose of imatinib exhibited the greatest impact on TPR and, even though the majority of patients completed the study at 200 mg or less, the magnitude of the hemodynamic change for the study was noted to compare favorably with recent studies of novel therapies added to background treatment. The Company believes this supports its thesis that IKT-001 has the potential to minimize GI side effects while maximizing the highly efficacious outcomes observed at 400 mg across multiple studies.

**Recent Developments:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Advancement of IKT-001 as a therapy in PAH:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• During the first half of 2025, the Company evaluated potential study designs and obtained feedback from various
key opinion leaders before finalizing a clinical study protocol for its forthcoming Phase 2b study, known as IMPROVE-PAH.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• IMPROVE-PAH is a multi-center, randomized, double-blind,
placebo-controlled study of approximately 150 PAH participants. Participants under IMPROVE-PAH will be randomized 1:1:1 to receive 300 mg IKT-001, 500 mg IKT-001, or placebo once daily for 26 weeks, in addition to stable background PAH therapy. The Company's bioequivalence studies previously confirmed that 500 mg of IKT-001 has comparable exposure in humans to 380 mg of imatinib. The primary efficacy endpoint is change in pulmonary vascular resistance at Week 26. Secondary endpoints include 6MWD, World Health Organization
functional class, and pharmacokinetics. The study protocol also includes an interim safety review for study continuance by the Data Safety Monitoring Board with at least 50 patients at 12-weeks of follow-up.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company expects to initiate IMPROVE-PAH in the second half of 2025.

------

![LOGO](g946023g58z24.jpg)

**Financial Results** 

**Cash Position:** As of June 30, 2025, cash, cash equivalents and marketable securities were $87.7 million as compared to $97.5 million as of December 31, 2024.

**Net Loss:** Net loss for the quarter ended June 30, 2025, was $9.9 million, or $0.11 per share, compared to a net loss of $5.0 million, or $0.66 per share in the quarter ended June 30, 2024. Net loss for the six months ended June 30, 2025, was $23.6 million, or $0.26 per share, compared to a net loss of $9.6 million, or $1.38 per share, for the six months ended June 30, 2024.

**R&D Expenses:** Research and development expenses were $5.3 million for the quarter ended June 30, 2025, compared to $3.1 million for the quarter ended June 30, 2024. Research and development expenses were $15.8 million for the six months ended June 30, 2025, which includes a non-cash write-off of in-process research and development of $7.4 million and $1.0 million of stock-based compensation expense, both associated with the Company's acquisition of CorHepta in February 2025, compared to $5.8 million for the six months ended June 30, 2024.

**SG&A Expenses:** Selling, general and administrative expenses for the quarter ended June 30, 2025 were $5.9 million, compared to $2.0 million for the quarter ended June 30, 2024. Selling, general and administrative expenses for the six months ended June 30, 2025 were $11.2 million, which includes $1.0 million of severance expenses resulting from the transition of senior executives in the Company during the year, compared to $4.0 million for the six months ended June 30, 2024.

**About Inhibikase (www.inhibikase.com)** 

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, PAH, that arise from aberrant signaling through the Abelson Tyrosine Kinase, and type III receptor tyrosine kinases including platelet derived growth factor receptors and c-KIT. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate, for PAH which is an orphan indication. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans.

**Social Media Disclaimer** 

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

------

![LOGO](g946023g58z24.jpg)

**Forward-Looking Statements** 

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the potential effects of IKT-001, the initiation of the Company's Phase 2b trial of IKT-001 in PAH and the Company's future activities, or future events or conditions. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to commence and execute a Phase 2b trial to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

**Contacts:** 

*Investor Relations:* 

Michael Moyer

LifeSci Advisors

mmoyer@lifesciadvisors.com

—tables to follow—

------

![LOGO](g946023g58z24.jpg)

**Inhibikase Therapeutics, Inc.** 

**Condensed Consolidated Balance Sheets** 

**(Unaudited)** 

---

| | | |
|:---|:---|:---|
|  | **June 30,**<br>**2025** | **December 31,**<br>**2024** |
|  | **(unaudited)** | **(Note 3)** |
|  **Assets** |  |  |
|  Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents | $77742669 | $56490579 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Marketable securities | 9923100 | 41052949 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid research and development | 138855 | 81308 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred offering costs | 307373 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses and other current assets | 682628 | 826473 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current assets | 88794625 | 98451309 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Equipment and improvements, net | 23687 | 47100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Right-of-use asset | 34918 | 101437 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $88853230 | $98599846 |
| **Liabilities and stockholders' equity** |  |  |
|  Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable | $2703554 | $943019 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lease obligation, current | 37944 | 110517 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued expenses and other current liabilities | 3145888 | 2680030 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contingent consideration liability | 2912159 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current liabilities | 8799545 | 3733566 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities | 8799545 | 3733566 |
|  Commitments and contingencies (see Note 16) |  |  |
|  Stockholders' equity: |  |  |
|  Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2025 and December 31, 2024 |  |  |
|  Common stock, $0.001 par value; 500,000,000 and 100,000,000 shares authorized; 74,516,635 and 69,362,439 shares issued and outstanding (including 4,149,252 and 0 contingently issuable shares—see Note 10) at June 30, 2025 and December 31, 2024, respectively | 74516 | 69362 |
|  Additional paid-in capital | 197996982 | 189254777 |
|  Accumulated other comprehensive loss | (2944) | (37248) |
|  Accumulated deficit | (118014869) | (94420611) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total stockholders' equity | 80053685 | 94866280 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities and stockholders' equity | $88853230 | $98599846 |

---

------

**Inhibikase Therapeutics, Inc.** 

**Condensed Consolidated Statements of Operations and Comprehensive Loss** 

**(Unaudited)** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six months ended June 30,** | **Six months ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  Costs and expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research and development | $5270967 | $3075830 | $15784546 | $5827109 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Selling, general and administrative | 5919731 | 1974705 | 11169022 | 4005786 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in fair value contingent consideration | (358420) |  | (1523284) |  |
|  Total costs and expenses | 10832278 | 5050535 | 25430284 | 9832895 |
|  Loss from operations | (10832278) | (5050535) | (25430284) | (9832895) |
|  Interest income | 916755 | 90927 | 1836026 | 223652 |
|  Net loss | (9915523) | (4959608) | (23594258) | (9609243) |
|  Other comprehensive income (loss), net of tax |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unrealized gain (loss) on marketable securities | (1977) | 776 | 34304 | (1901) |
|  Comprehensive loss | $(9917500) | $(4958832) | $(23559954) | $(9611144) |
|  Net loss per share – basic and diluted | $(0.11) | $(0.66) | $(0.26) | $(1.38) |
|  Weighted-average number of shares – basic and diluted | 90009625 | 7535667 | 89774703 | 6939779 |

---

------

**Inhibikase Therapeutics, Inc.** 

**Condensed Consolidated Statements of Cash Flows** 

**(Unaudited)** 

---

| | | |
|:---|:---|:---|
|  | **Six months ended June 30,** | **Six months ended June 30,** |
|  | **2025** | **2024** |
|  **Cash flows from operating activities** |  |  |
|  Net loss | $(23594258) | $(9609243) |
|  Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation | 36812 | 13137 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation expense | 6250938 | 84131 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Write-off of in-process research and development | 7357294 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in fair value of contingent consideration | (1523284) |  |
|  Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease right-of-use assets | 66519 | 58465 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses and other assets | 7526 | 30719 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid research and development | (57547) | (86483) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable | 1592656 | 875701 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease liabilities | (72573) | (62389) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued expenses and other current liabilities | 258156 | (225430) |
|  Net cash used in operating activities | (9677761) | (8921392) |
|  **Cash flows from investing activities** |  |  |
|  Purchases of equipment and improvements | (13399) |  |
|  Purchases of investments—marketable securities |  | (9209545) |
|  Maturities of investments—marketable securities | 31350103 | 8440958 |
|  Acquired in-process research and development | (438624) |  |
|  Net cash provided by (used in) investing activities | 30898080 | (768587) |
|  **Cash flows from financing activities** |  |  |
|  Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs | 150 | 3611255 |
|  Issuance of common stock form exercise of stock options | 31621 |  |
|  Net cash provided by financing activities | 31771 | 3611255 |
|  Net increase (decrease) in cash and cash equivalents | 21252090 | (6078724) |
|  Cash and cash equivalents at beginning of period | 56490579 | 9165179 |
|  Cash and cash equivalents at end of period | $77742669 | $3086455 |
|  **Supplemental disclosures of cash flow information** |  |  |
|  Issuance costs | $— | $1203350 |
|  **Non cash investing and financing activities** |  |  |
|  Non-cash financing costs | $— | $(181930) |
|  CorHepta transaction costs | $175000 | $— |
|  Contingent consideration | $2912159 | $— |
|  Deferred offering costs included in accounts payable and accrued expenses | $307373 | $— |

---

## Exhibit 99.2

![Slide 1](g946023ex99_2s1g1.jpg)

Corporate Overview August 2025 Exhibit 99.2

------

![Slide 2](g946023ex99_2s2g1.jpg)

Disclaimer This presentation contains information that may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Inhibikase Therapeutics, Inc. (the "Company" or "we") intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in those sections. Generally, we have identified such forward-looking statements by using the words "believe," "expect," "intend," "estimate," "anticipate," "project," "target," "forecast," "aim," "should," "will," "may", "continue", "assume", "contemplate", "could", "design", "due", "goal", "hope", "might", "plan", "opportunity", "predict", "possible", "potential", "seek", "strategy", "would" and similar expressions that are predictions or indicate future events and future trends, or the negative of these terms or other comparable terminology. Such statements are subject to a number of assumptions, risks and uncertainties which may cause actual results, performance or achievements to be materially different from those anticipated in these forward-looking statements. You should read statements that contain these words carefully because they discuss future expectations and plans which contain projections of future clinical studies or trials, regulatory approvals, product candidate development, results of operations or financial condition or state other forward-looking information. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements are not historical facts, but instead represent only the Company's beliefs regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Management believes that these forward-looking statements are reasonable as of the time made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Company's historical experience and our present expectations or projections. This presentation should be read in conjunction with the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K, its quarterly Form 10-Q and any subsequent filings with the SEC (collectively, the "SEC Filings"). Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company's SEC filings, including under the caption "Risk Factors". Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, we have not independently verified , and make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources. In addition, no independent sources has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in this presentation related to or based on such internal estimates and research. We do not intend our use or display of other entities' names, trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

------

![Slide 3](g946023ex99_2s3g1.jpg)

CHRIS CABELL, MD MHS FACC Head of R&D, Chief Medical Officer MARK IWICKI Chief Executive Officer JOHN ADAMS, PHD Chief Scientific Officer DAVID McINTYRE BEC CPA LLB MBA Chief Financial Officer CHAD OREVILLO, MPH EVP, Development Operations ALLISON WIDLITZ, MS, PA VP, Clinical Development JEFF KAGY Chief Human Resource Officer Experienced Leadership with Deep Expertise in PAH

------

![Slide 4](g946023ex99_2s4g1.jpg)

Inhibikase and IKT-001: Pulmonary Arterial Hypertension (PAH) PAH is a rare, progressive and life-threatening disease with significant unmet need ~30% 5-year mortality(1), reduced quality of life and high economic burden $7.6 Billion market with limited treatments that address the underlying etiology Imatinib is an anti-proliferative TKI with potential best-in-class improvements in PVR and 6MWD (45 meters\*) based on Phase 3 IMPRES and Phase 2 studies Imatinib hit primary efficacy endpoints in IMPRES but was not well tolerated at 400mg IKT-001 is a pro-drug engineered to realize the potential of imatinib in PAH IKT-001 releases imatinib in the blood with potential to minimize GI side effects maximizing potential to achieve highly efficacious doses IKT's Phase 2b is on track to initiate in the second half of 2025 Long intellectual property runway through 2044 Team with extensive PAH / CV experience Major unmet need with high mortality, poor QoL and high cost Imatinib has proven efficacy in Phase 3 in PAH Strong Leadership Executing Near Term Development Potential to be the 1st oral anti-proliferative agent (1) Hoeper M, et al. Eur Respir J. 2017 TKI = tyrosine kinase inhibitor; QoL= Quality of Life; PVR = pulmonary vascular resistance; 6MWD = 6-minute walk distance; GI= Gastrointestinal; CV = cardiovascular \* See Page 17

------

![Slide 5](g946023ex99_2s5g1.jpg)

PAH is a Progressive Disease Driven by Uncontrolled Cell Proliferation Proliferation of vascular cells drive vascular remodeling, raising pulmonary artery pressure and leading to progressive right ventricular heart failure and ultimately death PASMCs = Pulmonary artery smooth muscle cells; Vascular smooth muscle cells

------

![Slide 6](g946023ex99_2s6g1.jpg)

PAH: An Orphan Disease with ~30% 5-Year Mortality Despite Aggressive Treatment ~50,000 People with PAH in the US(1) ~26,000 People with PAH in the EU5(1) ~80% Female(2) 52 years Average age at diagnosis(2) (1) CVrG Market Strategies report Jun 2025; (2) Badlam et al; CHEST 2021; (3) Hoeper M, et al. Eur Respir J. 2017; (4) Watzger et al; Pharmacoeconomics 2025 Progressive and Life Threatening ~30% 5-year mortality(3) despite aggressive treatment with vasodilator therapies Progressively worsening symptoms Reduced Quality of Life Chronic breathlessness, and fatigue Significant limitation on activities of daily living Dizziness, chest pain, anxiety and depression High Economic Burden4 Average monthly healthcare costs ~$6,850-$15,650 Acute all cause hospitalization rate of 700 per 1000 patients per year among Medicare or Medicaid patients Substantial indirect costs due to work loss, caregiver time and disability 15 Approved vasodilators (across the prostacyclin, nitric oxide, and endothelin pathways) 1 Approved anti-proliferative High Unmet Medical Need

------

![Slide 7](g946023ex99_2s7g1.jpg)

PAH: Patient and Treatment Journey CONFIDENTIAL Initiate PDE-5i +ERA Combo Oral/Inhaled Prostacyclin Activin Signaling Inhibitor Infused Prostacyclin PDE-5i or •NO Pathway Sildenafil; Tadalafil; Riociguat\* ERA's Bosentan; AmbrisentanMacitentan Selexipag; Oral Remodulin; Tyvaso, Tyvaso DPI; Yutrepia Sotatercept Remodulin IV; Remodulin Sub-Q; Flolan, Veletri Progressive pulmonary vasculopathy driving right heart failure (RHF) ESC/ERS 4 Risk Strata (Risk of 1 year Mortality)(1) Low (0-3%) Intermediate Low (2-7%) Intermediate High (9-19%) High (>20%) WHO Functional Class Class 1 No limitation of physical activity Class 1 No limitation of physical activity Class 2 Slight limitation of physical activity. Ordinary physical activity causes dyspnea, fatigue, chest pain, or near syncope Class 3 Marked limitation in physical activity. Less than ordinary activity causes undue dyspnea, fatigue, chest pain or near syncope Class 4 Inability to carry out any physical activity without symptoms. Signs of RHF. Discomfort increased by any physical activity. Dyspnea and fatigue present at rest 6MWD >440 meters >440 meters 320 – 440 meters 165 - 319 meters <165 meters NT-ProBNP <300ng.L-1 <300ng.L-1 300-649ng.L-1 650-1100ng.L-1 >1100ng.L-1 (1) Humbert et al; ERJ 2023 1st Line of Therapy Add On Therapy With Declining Health Status ERS=European Respiratory Society; ESC=European Society of Cardiology; WHO=World Health Organization; 6MWD= 6 Minute Walk Distance Test; NT-ProBNP= Biomarker of cardiac strain; NO = Nitric Oxide; \* Riociguat is a soluble guanylate cyclase stimulator (sGC)

------

![Slide 8](g946023ex99_2s8g1.jpg)

Nitric Oxide Pathway ($1.0B) $7.6B Market Driven by Vasodilators Which Don't Treat Underlying Causes of PAH Novel antiproliferative agents with disease modifying properties expected to revolutionize treatment 2024 annual reports from Janssen, United Therapeutics, Bayer, and Merck Sildenafil, Tadalafil, Riociguat Sotatercept - subcutaneos injection (FDA approval March 2024) Ambrisentan, Bosentan, Macitentan Epoprostenol, Treprostinil, Iloprost, Selexipag $3.7B $1.0B $0.4B $2.5B Prostacyclin Pathway ($3.7B) Activin Signaling Pathway ($0.4B) Endothelin Pathway ($2.5B) Anti-proliferative Agents Vasodilators $3.7B $1.0B $0.4B $2.5B IKT-001 has the potential to be the first oral anti-proliferative agent for the treatment of PAH

------

![Slide 9](g946023ex99_2s9g1.jpg)

Our Solution: An Oral Pro-Drug of Imatinib Optimized for PAH Engineered to realize imatinib's best-in-class efficacy potential in PAH Gleevec (Imatinib) IKT-001 (Imatinib Pro-Drug) History First Approved in 2001; 25 years of real-world experience Indicated for: Leukemia, Soft Tissue Sarcoma, Myelodysplastic Syndromes, Mastocytosis and GIST PAH Data Best-in-class improvements in PVR and 6MWD in Phase 2 & 3 Greatest efficacy at 400mg but not clinically tolerated Contemporary study supports 400mg efficacy/tolerability findings IKT-001 is a novel pro-drug of imatinib designed for better GI tolerability allowing optimal efficacy Potential to be the first and only once-daily oral anti-proliferative tyrosine kinase inhibitor (TKI) for PAH PVR = Pulmonary Vascular Resistance; 6MWD= 6 Minute Walk Distance test; GI = Gastrointestinal; GIST = Gastrointestinal Stromal Tumor

------

![Slide 10](g946023ex99_2s10g1.jpg)

2024 2025 2026 2027 2028 H1 H2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Clinical Development Regulatory Development and Regulatory Timeline Pre-IND Meeting with FDA KOL Feedback: Refining Ph 2b Protocol Phase 2b (n=150) IKT-001 v Placebo Interim Safety Analysis Topline data FDA File Ph 2b Protocol EU File Ph 2b Protocol File for Orphan Drug Designation With FDA FDA "Authorization to Proceed" Global Site selection and activation

------

![Slide 11](g946023ex99_2s11g1.jpg)

Scientific and Clinical Rationale

------

![Slide 12](g946023ex99_2s12g1.jpg)

Imatinib Mechanism of Action in PAH Targets the Underlying Cause of PAH CONFIDENTIAL Modified from Savage and Antman, 2005 and Barst, R J Clin Invest 2005 Overactive kinases implicated in aberrant cell proliferation and migration in the pulmonary vasculature Imatinib inhibits the tyrosine kinase activity of PDGFR and c-kit , blocking cell signaling that drives vascular remodeling Pulmonary vasculature with aberrant cell proliferation Normal pulmonary vasculature Adventitia VSMCs Internal elastic lamina Microfibroblasts and extracellular matrix (neointima) Endothelium Adventitia VSMCs Internal elastic lamina Endothelium Imatinib inhibits the tyrosine kinase activity of PDGFR and c-kit , blocking cell signaling that drives vascular remodeling Proliferation

------

![Slide 13](g946023ex99_2s13g1.jpg)

Imatinib Demonstrated Reversal of PAH in Standard Animal Model Day 0 MCT d42 MCT d42/+imatinib Schermuly et al., JCI 2005 Reversal of right ventricular pressure Improved survival Reversal of vascular remodeling STI571 = imatinib; MCT = monocrotaline \*P < 0.05 versus control; †P < 0.05 versus MCT at day 28 or hypoxia at day 21; ‡P < 0.05 versus MCT at day 42 or hypoxia at day 35. Imatinib reverses pulmonary vascular remodeling, right ventricular pressure / remodeling and improves survival

------

![Slide 14](g946023ex99_2s14g1.jpg)

IMPRES – Imatinib Phase 3 Study Randomized, double blind, placebo controlled study to assess the efficacy, safety and tolerability of 400mg imatinib once daily (n=202) Primary Endpoint Change in 6MWD at 24 weeks Secondary Endpoints Changes in hemodynamics (PVR, CO, mPAP, RAP) at 24 weeks Time to clinical worsening Weeks 0 4 8 12 16 20 24 Imatinib (n=103) Placebo (n=99) Titration 200mg 400mg with ability to down titrate to 200mg if unable to tolerate 400mg Key Inclusion Criteria Functional Class II-IV 2 or more background PAH therapies PVR ≧ 800 dynes.s.cm-5 6MWD ≥150 meters and ≤ 450meters PVR = pulmonary vascular resistance; CO = cardiac output; mPAP = mean pulmonary arterial pressure; RAP = right arterial pressure; 6MWD = 6-minute walk distance

------

![Slide 15](g946023ex99_2s15g1.jpg)

Phase 3 IMPRES: Statistically Significant Improvement in Function & Hemodynamics 32-meter improvement in 6WMD and 32% reduction in PVR at week 24 Hoeper et al; Circulation 2013 Phase 3 IMPRES study hit its primary endpoint along with key clinically relevant secondary endpoints Change in 6MWD Change in Pulmonary Vascular Resistance Change in Cardiac Output PVR = Pulmonary Vascular Resistance; 6MWD= 6 Minute Walk Distance test

------

![Slide 16](g946023ex99_2s16g1.jpg)

Phase 3 IMPRES: 3 of the Top 5 AEs were GI Related Majority of patients were unable to maintain 400 mg target dose of imatinib Hoeper et al; Circulation 2013 AE = Adverse event; GI = Gastrointestinal Phase 3 IMPRES hit its primary endpoint DESPITE only 48/103 participants maintaining 400mg dose for at least half of the treatment period Imatinib n=103 (%) Placebo n=98 (%) Adverse Events 100 (97) 94 (96) Nausea 57 (55) 23 (24) Peripheral edema 45 (44) 20 (20) Diarrhea 36 (35) 19 (19) Vomiting 31 (30) 10 (10) Periorbital edema 30 (29) 7 (7) The AE profile in IMPRES was similar to the established AE profile of imatinib in other indications Poor tolerance prevented most patients from maintaining the target dose of 400 mg of imatinib IKT-001 is a novel pro-drug of imatinib designed for better GI tolerability allowing optimal efficacy

------

![Slide 17](g946023ex99_2s17g1.jpg)

IMPRES: Efficacy Impacted by Tolerability of 400mg Per Day Patients able to sustain 400mg dose showed greater improvements in 6MWD and PVR Changes in PVR at Week 24 Changes in 6MWD at Week 24 N=40 N=24 N=79 N=44 N=23 N=78 Hoeper et al; Circulation 2013 Suppl. Appendix Meters Dynes/sec/cm-5 (Baseline\*: 355 meters imatinib; 366 meters placebo) (Baseline\*: 1202 dynes/sec/cm-5 imatininb; 1181 dynes/sec/cm-5 placebo) \* Baseline data is not available for the sub-population of patients on 400mg of imatinib for > 50% of treatment so baseline data above reflects entire study population. PVR= Pulmonary vascular resistance; 6MWD = 6-minute walk distance 45 meter placebo adjusted improvement in 6MWD

------

![Slide 18](g946023ex99_2s18g1.jpg)

Contemporary Study of Imatinib Supports 400mg Dose for Best Efficacy Higher Exposure associated with larger treatment effect Higher Exposure = Larger Improvement More than 50% of subjects who completed the study were on 200mg per day or less One-third of patients who started the study at either 300mg or 400mg had dose-limiting toxicity at Week 4 and subsequent dose reduction Only 5 patients completed the study at 300mg or 400mg per day Percentage change in total pulmonary resistance from baseline at 60 days in relation to plasma level (area under curve in μg\*h/L) of imatinib at steady state (red-100md QD, orange-200mgQD, cyan-300mg QD, blue-400mg QD) Doses over 200mg per day were poorly tolerated \* Rothman et al., AJRCCM 2025. 17 patient open-label study. Patients were implanted with the CardioMEMS HF System which is a small, wireless sensor implanted in the pulmonary artery to monitor pulmonary artery pressure. Patients remained in the study for up to 24 weeks.

------

![Slide 19](g946023ex99_2s19g1.jpg)

Rapid and Sustained Hemodynamic Effect & Disease Modification of Imatinib in PAH Early & Continued Improvement 24% reduction in Total Pulmonary Resistance (TPR); Patients at 200mg or less leaves "efficacy on the table" 24% Reduction in TPR Early Improvement in TPR Slow return to BL \* Rothman et al., AJRCCM 2025. 17 patient open-label study. Patients were implanted with the CardioMEMS HF System which is a small, wireless sensor implanted in the pulmonary artery to monitor pulmonary artery pressure. Patients remained in the study for up to 24 weeks. 2 Slow return to baseline suggests disease modification 3 1

------

![Slide 20](g946023ex99_2s20g1.jpg)

------

![Slide 21](g946023ex99_2s21g1.jpg)

>2.5x Improvement in GI Tolerability Dose Associated with GI Toxicity Imatinib: 75 mg per kg per day IKT-001: 200 mg per kg per day IKT-001 Minimizes GI Imatinib Exposure to Drive Increased Tolerability 28 Day non-human primate study documents improved GI tolerability imatinib enzymatic cleavage blood gut Pro-drug linker gut wall IKT-001 IKT-001 GI = gastrointestinal

------

![Slide 22](g946023ex99_2s22g1.jpg)

IKT-001-201: A Phase 2b Study of IKT-001 in PAH Randomized double-blind, placebo-controlled study to evaluate efficacy and safety of once daily IKT-001 Primary Endpoints: PVR at week 26, change from baseline Safety and tolerability Secondary Endpoints: 6MWD WHO Functional Class Pharmacokinetics Inclusion / Stratification: WHO Group 1 PAH with New York Heart Association Functional Class II / III symptoms Baseline Right Heart Catheter performed during screening period: PVR of ≥400 dynes/sec/cm-5 ; PCWP ≤15 mmHg; mPAP >20 mmHg PVR enrichment criteria to ensure population baseline PVR >700 dynes/sec/cm-5 6MWD ≥100 and ≤500 meters Previous sotatercept allowed if discontinued 6 months prior to screening and no history of serious bleeding events Stratification by number of background therapies and ERS/ESC Risk Score Screening Period 26-Week Treatment Period IKT-001: 300 mg QD x 2 weeks then 500 mg QD (n=50) IKT-001: 300 mg QD (n=50) Placebo QD (n=50) 1:1:1 randomization Study Visit Study Week SV Days -28 to -1 1 2 3 4 5 6 7 BL Day 1 2 6 10 14 20 26 EOT EOS Two weeks after last dose RHC RHC Open Label Extension PVR = pulmonary vascular resistance; 6MWD = 6-minute walk distance; RHC = right heart catheter; PCWP = pulmonary capillary wedge pressure; mPAP = mean pulmonary arterial pressure; BL = baseline; SV = screening visit; EOT = end of treatment; EOS = end of study Up to 120 sites in 18 countries

------

![Slide 23](g946023ex99_2s23g1.jpg)

Inhibikase and IKT-001: Pulmonary Arterial Hypertension (PAH) Anthos: Key Investment Highlights PAH is a rare, progressive and life-threatening disease with significant unmet need ~30% 5-year mortality(1), reduced quality of life and high economic burden $7.6 Billion market with limited treatments that address the underlying etiology Imatinib is an anti-proliferative TKI with potential best-in-class improvements in PVR and 6MWD (45 meters\*) based on Phase 3 IMPRES and Phase 2 studies Imatinib hit primary efficacy endpoints in IMPRES but was not well tolerated at 400mg IKT-001 is a pro-drug engineered to realize the potential of imatinib in PAH IKT-001 releases imatinib in the blood with potential to minimize GI side effects maximizing potential to achieve highly efficacious doses IKT's Phase 2b is on track to initiate in the second half of 2025 Long intellectual property runway through 2044 Team with extensive PAH / CV experience Major unmet need with high mortality, poor QoL and high cost Imatinib has proven efficacy in Phase 3 in PAH Strong Leadership Executing Near Term Development Potential to be the 1st oral anti-proliferative agent (1) Hoeper M, et al. Eur Respir J. 2017 TKI = tyrosine kinase inhibitor; QoL= Quality of Life; PVR = pulmonary vascular resistance; 6MWD = 6-minute walk distance; GI= Gastrointestinal; CV = cardiovascular \* See Page 17

------

![Slide 24](g946023ex99_2s24g1.jpg)

Thank You